Two prominent Indian Vaccines enter Human Trials, Maybe in use by August 15

The whole world today is battling with the unseen Coronavirus, Covid-19. India too is fighting its own battle with Coronavirus. With around 20,000 cases reported in a day, today India has 6,26,000 cases with 3,80,000 recoveries and 18,000 deaths. The rate of recovery in India is at 59%, higher than the world average recovery rate.

Among all these news,Over 7 vaccines are being researched in India and just in the week, two candidate groups are given the go-ahead to start out human clinical trials for his or her prototypes.

In some positive development, Indian drug company , Zydus Cadila received the green signal from The Drug Controller General of India (DGCI) to start out phase I clinical trial and II of their clinical trials on human participants.The news comes just after India’s first homegrown vaccine, Bharat Biotech’s COVAXIN received the approvals to start out with their clinical trials.

While India is one among the leading vaccine producers and suppliers within the world and it takes tons of your time for a vaccine to undergo stages, trials are being wiped out a speedy way across the planet to satisfy the surge of the pandemic that has caused widescale destruction.

The institutes are asked by the ICMR to intensify clinical trials because it may be a “priority project” monitored at the topmost level of the govt.

“The vaccine springs from a strain of SARS-CoV-2 isolated by ICMR-National Institute of Virology, Pune. ICMR and BBIL are jointly working for the pre-clinical also as clinical development of this vaccine,” the ICMR said during a letter to the institutes.

The ICMR talked about plans to launch the vaccine for public healthuse by, Independence Day.

“It is envisaged to launch the vaccine for public health use latest by 15th August 2020 after completion of all clinical trials,” said the research body.

The final outcome will depend upon the cooperation of all clinical test sites involved during this project, the ICMR told the institutes, advising them to hurry up approvals associated with clinical trials and make sure that subjects are enrolled starting in the week .

“Non-compliance are going to be viewed very seriously. Therefore, you’re advised to treat this project on highest priority and meet the given timelines with none lapse,” said ICMR’s letter.

There are 12 institutes selected all over India for the clinical test which are in Visakhapatnam, Rohtak, New Delhi, Patna, Belgaum (Karnataka), Nagpur, Gorakhpur, Kattankulathur (Tamil Nadu), Hyderabad, Arya Nagar, Kanpur (Uttar Pradesh) and Goa.

Till this date there’s no vaccine that has been approved to treat Covid-19.